$BMY

Bristol Myers Squibb and Novartis halted clinical trials for CAR-T therapies targeting autoimmune diseases due to safety concerns. Bristol Myers paused a zola-cel study after detecting ICANS cases, while Novartis suspended rap-cel trials following three patient deaths. Both companies are investigating the issues, with Bristol Myers reporting non-fatal effects and Novartis analyzing data. The trials aimed to treat diseases like lupus and rheumatoid arthritis, with initial results showing promise.

Bristol Myers Squibb (BMY) reported five-year data for Camzyos, showing sustained efficacy and safety in treating obstructive hypertrophic cardiomyopathy, supported by real-world studies. The data strengthens Camzyos' market position and may influence clinical management. The company projects $40B revenue and $8.3B earnings by 2029, with analysts' estimates varying. The pause in zola cel trials highlights risks in BMS's pipeline.

Bristol Myers Squibb (BMY) presented positive five-year data for Camzyos at ESC 2026, showing sustained efficacy and safety in treating oHCM. Sales surged 74% YoY to $729M in H1 2026. The FDA accepted a sNDA for adolescent use, with a decision expected by Sept. 30, 2026. Competitors include Cytokinetics (CYTK) with Myqorzo and Edgewise Therapeutics (EWTX) with EDG-7500. BMY shares gained 20.3% YTD, trading at 10.35X forward earnings.

Novartis halted eight clinical trials of its experimental cell therapy rap-cel after three patients died from severe immune reactions. The pause affects trials for autoimmune and neurological disorders. Novartis is reviewing the deaths and sharing information with health authorities. Bristol Myers also paused studies of its rival CAR T-cell treatment zola-cel. Novartis shares rose 4% on Tuesday.

Reports of a potential merger between AstraZeneca (AZN) and Bristol Myers Squibb (BMY) caused a 5% drop in AstraZeneca's shares, wiping £17 billion off its market value. Both companies denied the reports, and analysts suggest antitrust scrutiny would be significant due to overlapping oncology businesses. The FTSE 100 traded flat, with oil prices also falling due to geopolitical developments.

A pilot program involving rural pharmacies in six U.S. states identified 10,000 at-risk patients for stroke and heart disease, with 20,000 interventions in six months. The initiative, a collaboration between NCPA, CPESN, and Bristol Myers Squibb, trained pharmacy staff to screen patients and connect them with necessary care, potentially saving lives and reducing healthcare costs. The program's success may lead to a second phase.

Moderna's market value surged $45B after positive cancer vaccine data. Ultragenyx gained FDA approval for Genglycos, its first gene therapy. BioMarin acquired Alesta Therapeutics for $275M. AstraZeneca scrapped a Phase 3 lung cancer trial. Argenx reported positive Phase 3 data for Vyvgart. Capricor's CEO indicated FDA willingness to review updated cell therapy submission.

Novartis halted eight trials of rapcabtagene autoleucel in autoimmune diseases after three patient deaths. The pause, effective Aug. 24, affects trials for lupus, rheumatoid arthritis, and other conditions. Bristol Myers Squibb also paused its zolacabtagene autoleucel trials as a precaution. Both companies are reviewing the incidents. Two lymphoma and leukemia trials of rapcabtagene autoleucel were not impacted.

Novartis and Bristol Myers Squibb have paused trials of their CAR-T cell therapies for autoimmune disorders due to safety concerns. Novartis reported fatal outcomes in three trials of Rap-cel, while Bristol Myers noted reversible inflammatory events in Zola-cel trials. Both companies are reviewing data and engaging with regulators. Analysts suggest faster manufacturing processes may be linked to the issues, affecting multiple biotech companies' stocks.

Cytokinetics (CYTK) presented additional results from ACACIA-HCM and MAPLE-HCM studies at the European Society of Cardiology Congress 2026, showing aficamten's benefits in non-obstructive HCM (nHCM) and superiority over metoprolol in obstructive HCM (oHCM). CYTK plans to submit an sNDA for aficamten in nHCM in Q4 2026. Myqorzo (aficamten) faces competition from Bristol Myers Squibb's (BMY) Camzyos and Edgewise Therapeutics' (EWTX) EDG-7500. CYTK shares are up 12.4% YTD, trading at 26.6X forward